Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor
Start Date
6/18/2026
Completion Date
11/1/2028
Summary
Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tasks such as writing, pouring, and eating. This study will assess if AGN-151607-DP is safe and effective by assessing adverse events and change in disease activity in adult participants with UL ET. AGN-151607-DP is an investigational drug being developed to treat UL ET. Participants will be randomly placed in treatment groups to receive either AGN151607-DP or matching placebo. Approximately 94 adult participants with upper limb essential tremor will be enrolled in approximately 40 sites in the United States/Canada. Participants will receive intramuscular injections of AGN-151607-DP or matching placebo. Duration of the study is approximately 72 weeks. The effect of the treatment will be checked by completion of questionnaires and side effects will be monitored by medical assessments.
Eligibility Criteria
Age Range: 18 years to 85 years
Interventions
AGN-151607-DP
Placebo for AGN-151607-DP
Conditions
Locations
Neuro Pain Research Center /ID# 277899
Fresno, California 93710
United States
Parkinson'S Disease & Movement Disorders Center Of Boca Raton /ID# 277079
Boca Raton, Florida 33486
United States
Charter Research - Winter Park /ID# 277875
Orlando, Florida 32803-1839
United States